MedPath

BAYER AG

BAYER AG logo
πŸ‡©πŸ‡ͺGermany
Ownership
Public
Established
1863-08-01
Employees
99.7K
Market Cap
$30.1B
Website
http://www.bayer.com

Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer

Phase 2
Completed
Conditions
Colorectal Neoplasms
Interventions
First Posted Date
2015-06-08
Last Posted Date
2018-11-07
Lead Sponsor
Bayer
Target Recruit Count
59
Registration Number
NCT02465502

Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study

Phase 1
Completed
Conditions
Medical Oncology
Interventions
First Posted Date
2015-05-29
Last Posted Date
2016-05-23
Lead Sponsor
Bayer
Target Recruit Count
14
Registration Number
NCT02457351

Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan

Phase 1
Completed
Conditions
Clinical Trial, Phase I
Interventions
First Posted Date
2015-05-28
Last Posted Date
2016-03-02
Lead Sponsor
Bayer
Target Recruit Count
14
Registration Number
NCT02456129

Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Phase 2
Terminated
Conditions
Lymphoma, Mantle-Cell
Interventions
First Posted Date
2015-05-27
Last Posted Date
2017-10-02
Lead Sponsor
Bayer
Target Recruit Count
4
Registration Number
NCT02455297

A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction

Phase 2
Completed
Conditions
Heart Failure
Interventions
Drug: BAY1142524
Drug: Placebo
First Posted Date
2015-05-22
Last Posted Date
2017-11-07
Lead Sponsor
Bayer
Target Recruit Count
49
Registration Number
NCT02452515

Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany

Completed
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
Drug: Radium-223-dichloride (Xofigo, BAY88-8223)
First Posted Date
2015-05-21
Last Posted Date
2021-11-02
Lead Sponsor
Bayer
Target Recruit Count
86
Registration Number
NCT02450812
Locations
πŸ‡©πŸ‡ͺ

Many Locations, Multiple Locations, Germany

Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions

Phase 1
Completed
Conditions
Neoplasms
Bone Diseases
Interventions
Drug: Radium Ra 223 dichloride (Xofigo, BAY88-8223)
Drug: paclitaxel
First Posted Date
2015-05-13
Last Posted Date
2016-11-30
Lead Sponsor
Bayer
Target Recruit Count
15
Registration Number
NCT02442063

Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel

Phase 1
Terminated
Conditions
Medical Oncology
Interventions
Drug: BAY1143269 tablet
First Posted Date
2015-05-08
Last Posted Date
2018-03-07
Lead Sponsor
Bayer
Target Recruit Count
15
Registration Number
NCT02439346

Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women

Phase 1
Completed
Conditions
Endometriosis
Interventions
Drug: BAY1128688
Drug: Placebo
First Posted Date
2015-05-05
Last Posted Date
2016-05-19
Lead Sponsor
Bayer
Target Recruit Count
51
Registration Number
NCT02434640

Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)

Completed
Conditions
Hypertension, Pulmonary
Interventions
First Posted Date
2015-04-29
Last Posted Date
2024-01-29
Lead Sponsor
Bayer
Target Recruit Count
882
Registration Number
NCT02428985
Locations
πŸ‡―πŸ‡΅

Many Locations, Multiple Locations, Japan

Β© Copyright 2025. All Rights Reserved by MedPath